Similar Items: Incidence proportion and divergent performance of risk factors for carbapenem-resistant Gram-negative bacteria bloodstream infections across haematological cohorts
- In vitro activity of eravacycline and comparator agents against Gram-negative and Gram-positive bacteria: results from China Antimicrobial Surveillance Network between 2017 and 2019
- Genomic epidemiology of carbapenem resistance in Acinetobacter baumannii in Chile
- Carbapenem resistance in community-acquired urinary tract infections caused by Klebsiella pneumoniae and Escherichia coli in Morocco: a multicentre study (January 2022–December 2023)‘Carbapenem resistance in community UTIs in Morocco’
- Treatment outcomes of daptomycin- and vancomycin-resistant Enterococcus faecium bloodstream infection
- Contemporary multicentre analysis of carbapenemases distribution among clinical carbapenem-resistant Enterobacterales in Lebanon
- Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens